Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 205

1.

Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma.

Song MK, Chung JS, Lee JJ, Jeong SY, Lee SM, Hong JS, Chong A, Moon JH, Kim JH, Lee SM, Kim SJ, Shin HJ.

Cancer Sci. 2013 Dec;104(12):1656-61. doi: 10.1111/cas.12282. Epub 2013 Oct 23.

2.

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

Johnson P, Federico M, Kirkwood A, Fosså A, Berkahn L, Carella A, d'Amore F, Enblad G, Franceschetto A, Fulham M, Luminari S, O'Doherty M, Patrick P, Roberts T, Sidra G, Stevens L, Smith P, Trotman J, Viney Z, Radford J, Barrington S.

N Engl J Med. 2016 Jun 23;374(25):2419-29. doi: 10.1056/NEJMoa1510093.

3.

Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O'Doherty M, Barrington S.

N Engl J Med. 2015 Apr 23;372(17):1598-607. doi: 10.1056/NEJMoa1408648.

4.

Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan is an effective regimen for advanced high-risk Hodgkin's lymphoma.

Avigdor A, Bulvik S, Levi I, Dann EJ, Shemtov N, Perez-Avraham G, Shimoni A, Nagler A, Ben-Bassat I, Polliack A.

Ann Oncol. 2010 Jan;21(1):126-32. doi: 10.1093/annonc/mdp271. Epub 2009 Jul 16.

PMID:
19608615
5.

Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma.

Ganesan P, Rajendranath R, Kannan K, Radhakrishnan V, Ganesan TS, Udupa K, Lakshmipathy KM, Mahajan V, Sundersingh S, Rajaraman S, Krishnakumar R, Sagar TG.

Ann Oncol. 2015 Jun;26(6):1170-4. doi: 10.1093/annonc/mdv077. Epub 2015 Feb 20.

PMID:
25701453
6.

[Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].

Niu Y, Shi YK, He XH, Feng FY, Zhou LQ, Gu DZ.

Zhonghua Zhong Liu Za Zhi. 2008 Aug;30(8):630-4. Chinese.

PMID:
19102946
7.

Factors affecting intrapatient liver and mediastinal blood pool ¹⁸F-FDG standardized uptake value changes during ABVD chemotherapy in Hodgkin's lymphoma.

Chiaravalloti A, Danieli R, Abbatiello P, Di Pietro B, Travascio L, Cantonetti M, Guazzaroni M, Orlacchio A, Simonetti G, Schillaci O.

Eur J Nucl Med Mol Imaging. 2014 Jun;41(6):1123-32. doi: 10.1007/s00259-014-2703-0. Epub 2014 Feb 22.

PMID:
24562647
8.

[Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].

Fu XH, Wang SS, Huang Y, Wang B, Huang HQ, Zhang L, Sun XF, Xu RH, Lin TY.

Ai Zheng. 2006 Aug;25(8):1013-8. Chinese.

PMID:
16965685
9.

Post-ABVD/pre-radiotherapy (18)F-FDG-PET provides additional prognostic information for early-stage Hodgkin lymphoma: a retrospective analysis on 165 patients.

Ciammella P, Filippi AR, Simontacchi G, Buglione M, Botto B, Mangoni M, Iotti C, Merli F, Marcheselli L, Bisi G, Ricardi U, Versari A.

Br J Radiol. 2016;89(1061):20150983. doi: 10.1259/bjr.20150983. Epub 2016 Mar 24.

PMID:
27022777
10.

Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.

Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H, Franke A, Koch P, de Wit M, Paulus U, Hasenclever D, Loeffler M, Müller RP, Müller-Hermelink HK, Dühmke E, Diehl V.

J Clin Oncol. 2007 Aug 10;25(23):3495-502. Epub 2007 Jul 2.

PMID:
17606976
11.

Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.

Tseng D, Rachakonda LP, Su Z, Advani R, Horning S, Hoppe RT, Quon A, Graves EE, Loo BW Jr, Tran PT.

Radiat Oncol. 2012 Jan 19;7:5. doi: 10.1186/1748-717X-7-5.

12.

Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma.

Song MK, Chung JS, Shin HJ, Moon JH, Lee JO, Lee HS, Lee SM, Lee GW, Lee SE, Kim SJ.

Cancer Sci. 2012 Mar;103(3):477-82. doi: 10.1111/j.1349-7006.2011.02164.x. Epub 2012 Jan 16.

13.

Prognostic significance of mid- and post-ABVD PET imaging in Hodgkin's lymphoma: the importance of involved-field radiotherapy.

Sher DJ, Mauch PM, Van Den Abbeele A, LaCasce AS, Czerminski J, Ng AK.

Ann Oncol. 2009 Nov;20(11):1848-53. doi: 10.1093/annonc/mdp071. Epub 2009 Jun 18.

PMID:
19541793
14.

ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.

Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA, Crump M, Djurfeldt MS, Chen BE, Shepherd LE; NCIC Clinical Trials Group.; Eastern Cooperative Oncology Group..

N Engl J Med. 2012 Feb 2;366(5):399-408. doi: 10.1056/NEJMoa1111961. Epub 2011 Dec 11.

15.

Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.

Kobe C, Kuhnert G, Kahraman D, Haverkamp H, Eich HT, Franke M, Persigehl T, Klutmann S, Amthauer H, Bockisch A, Kluge R, Wolf HH, Maintz D, Fuchs M, Borchmann P, Diehl V, Drzezga A, Engert A, Dietlein M.

J Clin Oncol. 2014 Jun 10;32(17):1776-81. doi: 10.1200/JCO.2013.53.2507. Epub 2014 May 5.

PMID:
24799482
16.

Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.

Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA, Burns BF, Winter JN, Horning SJ, Dar AR, Djurfeldt MS, Ding K, Shepherd LE; National Cancer Institute of Canada Clinical Trials Group.; Eastern Cooperative Oncology Group..

J Clin Oncol. 2005 Jul 20;23(21):4634-42. Epub 2005 Apr 18.

PMID:
15837968
17.

The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma.

Burger IA, Vargas HA, Goldman DA, Gonen M, Kumar A, Zelenetz AD, Schöder H, Hricak H.

Eur J Nucl Med Mol Imaging. 2013 May;40(5):701-7. doi: 10.1007/s00259-012-2335-1. Epub 2013 Feb 7.

18.

Interim PET After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the Continuation of Chemotherapy Plus Radiotherapy.

Simontacchi G, Filippi AR, Ciammella P, Buglione M, Saieva C, Magrini SM, Livi L, Iotti C, Botto B, Vaggelli L, Re A, Merli F, Ricardi U.

Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1077-1083. doi: 10.1016/j.ijrobp.2015.04.021. Epub 2015 Apr 17.

PMID:
26031367
19.

Interim fluoro-2-deoxy-D-glucose-PET predicts response and progression-free survival in patients with Hodgkin lymphoma and HIV infection.

Okosun J, Warbey V, Shaw K, Montoto S, Fields P, Marcus R, Virchis A, McNamara C, Bower M, Cwynarski K.

AIDS. 2012 Apr 24;26(7):861-5. doi: 10.1097/QAD.0b013e32835213b1.

PMID:
22333746
20.

Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial.

Behringer K, Goergen H, Hitz F, Zijlstra JM, Greil R, Markova J, Sasse S, Fuchs M, Topp MS, Soekler M, Mathas S, Meissner J, Wilhelm M, Koch P, Lindemann HW, Schalk E, Semrau R, Kriz J, Vieler T, Bentz M, Lange E, Mahlberg R, Hassler A, Vogelhuber M, Hahn D, Mezger J, Krause SW, Skoetz N, Böll B, von Tresckow B, Diehl V, Hallek M, Borchmann P, Stein H, Eich H, Engert A; German Hodgkin Study Group.; Swiss Group for Clinical Cancer Research.; Arbeitsgemeinschaft Medikamentöse Tumortherapie..

Lancet. 2015 Apr 11;385(9976):1418-27. doi: 10.1016/S0140-6736(14)61469-0. Epub 2014 Dec 22. Erratum in: Lancet. 2015 Apr 11;385(9976):1396.

PMID:
25539730

Supplemental Content

Support Center